Skip to main content

Advertisement

SpringerLink
Log in

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

  • ASO Perspectives
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021;39(13):1485–505.

    Article  CAS  Google Scholar 

  2. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017;376(22):2147–59.

    Article  CAS  Google Scholar 

  3. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617–28.

    Article  Google Scholar 

  4. Boughey JC, Peintinger F, Meric-Bernstam F, et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006;244(3):464–70.

    Article  Google Scholar 

  5. Boughey JC, Ballman KV, McCall LM, et al. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance). Ann Surg. 2017;266(4):667–76.

    Article  Google Scholar 

  6. Tung NM, Boughey JC, Pierce LJ, et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol. 2020;38(18):2080–106.

    Article  CAS  Google Scholar 

  7. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810–21.

    Article  CAS  Google Scholar 

  8. National Comprehensive Cancer Network. Breast Cancer (Version 8.2021). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed November 3, 2021.

  9. Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–9.

    Article  CAS  Google Scholar 

  10. https://clinicaltrials.gov/ct2/show/NCT03628066.

  11. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372(2):134–41.

    Article  Google Scholar 

  12. Kuerer HM, Hunt KK. Limiting Axillary Surgery for Patients with Initial Biopsy-Proven Axillary Metastases After Preoperative Chemotherapy: To Clip or Not to Clip? Ann Surg Oncol, Vol 23, United States2016; 3432-3434.

  13. Elmore LC, Kuerer HM, Barcenas CH, et al. Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2021;28(10):5477–85.

    Article  Google Scholar 

  14. Relation T, Obeng-Gyasi S, Bhattacharyya O, et al. Racial Differences in Response to Neoadjuvant Chemotherapy: Impact on Breast and Axillary Surgical Management. Ann Surg Oncol. 2021;28(11):6489–97.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Nina Tamirisa MD & Kelly K. Hunt MD

Authors
  1. Nina Tamirisa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kelly K. Hunt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kelly K. Hunt MD.

Ethics declarations

KKH reports the following disclosures: Armada Health — Medical Advisory Board, Merck & Co. — Medical Advisory Board, Research funding to my institution — Lilly & Co. Research funding to my institution — Cairn Surgical, Research funding to my institution — Lumicell.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tamirisa, N., Hunt, K.K. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Ann Surg Oncol 29, 1489–1492 (2022). https://doi.org/10.1245/s10434-021-11223-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-11223-3

Search

Navigation